{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:39:24Z","timestamp":1790800764513,"version":"4.1.0"},"reference-count":152,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013412","name":"Sanofi Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.trre.2023.100795","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T19:44:46Z","timestamp":1695325486000},"page":"100795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The use of lymphocyte-depleting antibodies in specific populations of kidney transplant recipients: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"37","author":[{"given":"Nuria","family":"Montero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Cruzado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Gutierrez-Dalmau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auxiliadora","family":"Mazuecos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asunci\u00f3n","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Belmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Calatayud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Oliveras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eulalia","family":"Sol\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentino","family":"Villanego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2023.100795_bb0005","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2023.100795_bb0010","article-title":"Interleukin 2 receptor antagonists for kidney transplant recipients","volume":"2010","author":"Webster","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.trre.2023.100795_bb0015","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00007890-199904150-00013","article-title":"A randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients","volume":"67","author":"Brennan","year":"1999","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240929","article-title":"Induction therapy in kidney transplant recipients: description of the practices according to the calendar period from the French multicentric DIVAT cohort","volume":"15","author":"Boucquemont","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.trre.2023.100795_bb0025","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/ajt.14603","article-title":"Comprehensive review of post-organ transplant hematologic cancers","volume":"18","author":"Dharnidharka","year":"2018","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"key":"10.1016\/j.trre.2023.100795_bb0030","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/ajt.14018","article-title":"The changing financial landscape of renal transplant practice: a National Cohort analysis","volume":"17","author":"Axelrod","year":"2017","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"key":"10.1016\/j.trre.2023.100795_bb0035","author":"Higgins"},{"key":"10.1016\/j.trre.2023.100795_bb0040","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.trre.2023.100795_bb0045","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ."},{"key":"10.1016\/j.trre.2023.100795_bb0050","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"10.1016\/j.trre.2023.100795_bb0055","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/tri.13800","article-title":"Decreased incidence of acute rejection without increased incidence of cytomegalovirus (CMV) infection in kidney transplant recipients receiving rabbit anti-thymocyte globulin without CMV prophylaxis - a cohort single-center study","volume":"34","author":"de Paula","year":"2021","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2023.100795_bb0060","doi-asserted-by":"crossref","DOI":"10.15171\/jnp.2020.08","article-title":"Comparison of clinical outcome of induction immunosuppressive therapy with thymoglobulin and standard therapy in kidney transplantation; a randomized double-blind clinical trial","volume":"9","author":"Shahbazian","year":"2019","journal-title":"J Nephropathol"},{"key":"10.1016\/j.trre.2023.100795_bb0065","first-page":"S293","article-title":"Single-bolus high-dose ATG for prophylaxis of rejection in renal transplantation - a prospective, randomized study","volume":"13","author":"Yussim","year":"2000","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2023.100795_bb0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.12659\/AOT.883792","article-title":"High graft protection and low incidences of infections, malignancies and other adverse effects with intraoperative high dose ATG-induction: a single centre cohort study of 760 cases","volume":"18","author":"Kaden","year":"2013","journal-title":"Ann Transplant"},{"key":"10.1016\/j.trre.2023.100795_bb0075","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.transproceed.2004.05.064","article-title":"Beneficial effect of concomitant induction with antilymphoblast globulin, cyclosporine, and steroids on long-term renal allograft outcome","volume":"36","author":"Koga","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0080","doi-asserted-by":"crossref","first-page":"412","DOI":"10.12659\/AOT.915885","article-title":"Infectious complications of induction therapies in kidney transplantation","volume":"24","author":"Bayraktar","year":"2019","journal-title":"Ann Transplant"},{"key":"10.1016\/j.trre.2023.100795_bb0085","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1097\/TP.0b013e318190659d","article-title":"20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients","volume":"86","author":"Cantarovich","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2023.100795_bb0090","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0161-5890(03)00072-5","article-title":"Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation","volume":"39","author":"Abou-Jaoude","year":"2003","journal-title":"Mol Immunol"},{"key":"10.1016\/j.trre.2023.100795_bb0095","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1111\/j.1600-6143.2011.03540.x","article-title":"Evaluation of alloreactivity in kidney transplant recipients treated with antithymocyte globulin versus IL-2 receptor blocker","volume":"11","author":"Cherkassky","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2023.100795_bb0100","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1159\/000182816","article-title":"Outcomes in African-Americans vs. Caucasians using thymoglobulin or interleukin-2 receptor inhibitor induction: analysis of USRDS database","volume":"29","author":"Jindal","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.trre.2023.100795_bb0105","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/infdis\/jiz194","article-title":"Different impact of rATG induction on CMV infection risk in D+R- and R+ KTRs","volume":"220","author":"Kaminski","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2023.100795_bb0110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.transproceed.2011.12.063","article-title":"Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study","volume":"44","author":"Kim","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/01.tp.0000268084.64888.f3","article-title":"Single bolus antithymocyte globulin versus Basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety","volume":"84","author":"Kyll\u00f6nen","year":"2007","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0120","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.transproceed.2018.02.088","article-title":"Thymoglobulin versus Basiliximab induction therapy in low-risk kidney transplant recipients: a single-center experience","volume":"50","author":"Lee","year":"2018","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0125","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.intimp.2011.07.012","article-title":"Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin","volume":"11","author":"Lib\u00f3rio","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.trre.2023.100795_bb0130","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1399-0012.2004.00148.x","article-title":"Cost-minimization study comparing SimulectR vs. ThymoglobulinR in renal transplant induction","volume":"18","author":"Lilliu","year":"2004","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2023.100795_bb0135","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.transproceed.2016.02.019","article-title":"Induction immunosuppressive therapy use in deceased donor kidney transplantation: 11-year experience in Veracruz, Mexico","volume":"48","author":"Martinez-Mier","year":"2016","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0140","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.transproceed.2020.01.054","article-title":"Low-dose thymoglobulin vs Basiliximab induction therapy in low-risk living related kidney transplant recipients: a prospective randomized trial","volume":"53","author":"Martinez-Mier","year":"2021","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0145","first-page":"10816","article-title":"Very low dose anti-Thymocyte globulins versus Basiliximab in non-immunized kidney transplant recipients","volume":"36","author":"Masset","year":"2023","journal-title":"Transpl Int Off J Eur Soc Organ Transplant"},{"key":"10.1016\/j.trre.2023.100795_bb0150","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1399-0012.2007.00774.x","article-title":"A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up","volume":"22","author":"Ciancio","year":"2008","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2023.100795_bb0155","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/FTD.0000000000000790","article-title":"Immunosuppressive drug-associated adverse event profiles in De novo kidney transplant recipients receiving Everolimus and reduced tacrolimus doses","volume":"42","author":"Miranda","year":"2020","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.trre.2023.100795_bb0160","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/01.TP.0000129812.68794.CC","article-title":"Sequential protocols using Basiliximab versus anti-Thymocyte globulins in renal-transplant patients receiving mycophenolate Mofetil and steroids","volume":"78","author":"Mourad","year":"2004","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0165","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1016\/S0041-1345(02)03487-5","article-title":"Bolus anti-thymocyte globulin induction in renal transplant recipients: a comparison with conventional ATG or anti\u2013interleukin-2 receptor antibody induction","volume":"34","author":"Nampoory","year":"2002","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0170","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/01.tp.0000198417.91135.1f","article-title":"Comparison of sequential protocol using basiliximab versus antithymocyte globulin with high-dose mycophenolate mofetil in recipients of a kidney graft from an expanded-criteria donor","volume":"81","author":"Pallet","year":"2006","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0175","doi-asserted-by":"crossref","first-page":"819","DOI":"10.4103\/1319-2442.135057","article-title":"Low-dose rabbit anti-thymoglobin globulin versus basiliximab for induction therapy in kidney transplantation","volume":"25","author":"Patel","year":"2014","journal-title":"Saudi J Kidney Dis Transplant"},{"key":"10.1016\/j.trre.2023.100795_bb0180","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.transproceed.2011.01.040","article-title":"Obesity in renal transplantation: the role of induction therapy on long-term outcomes","volume":"43","author":"Patel","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0185","first-page":"5","article-title":"Effect of induction therapy on outcomes of de novo renal transplant recipients receiving everolimus with reduced-dose calcineurin inhibitor: 24-month results from transform study","volume":"33","author":"Pernin","year":"2020","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2023.100795_bb0190","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/SLA.0000000000000496","article-title":"Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation","volume":"259","author":"Pilch","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.trre.2023.100795_bb0195","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1093\/ndt\/16.5.1028","article-title":"An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation","volume":"16","author":"Polsky","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2023.100795_bb0200","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1016\/j.transproceed.2008.08.130","article-title":"Long-term efficacy of induction therapy with anti\u2013Interleukin-2 receptor antibodies or thymoglobulin compared with no induction therapy in renal transplantation","volume":"40","author":"Taber","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0205","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/tri.12991","article-title":"Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation: a health economic analysis from a German perspective","volume":"30","author":"Cremaschi","year":"2017","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2023.100795_bb0210","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/S0140-6736(16)32187-0","article-title":"Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (harmony): an open-label, multicentre, randomised controlled trial","volume":"388","author":"Thomusch","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.trre.2023.100795_bb0215","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0041-1345(03)00679-1","article-title":"ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results","volume":"35","author":"Tullius","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0220","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.1399-0012.2012.01656.x","article-title":"A CD3+ count-based thymoglobulin induction regimen permits delayed introduction of calcineurin inhibitors in kidney transplantation","volume":"26","author":"Wang","year":"2012","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2023.100795_bb0225","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.transproceed.2008.08.082","article-title":"Induction treatment with low-dose thymoglobulin or Basiliximab in renal transplants from older donors","volume":"40","author":"Gavela Mart\u00ednez","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0230","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.transproceed.2011.01.035","article-title":"Low-dose rabbit antithymocyte globulin versus Basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up","volume":"43","author":"Laftavi","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0235","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.intimp.2011.07.012","article-title":"Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin","volume":"11","author":"Liborio","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.trre.2023.100795_bb0240","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.transproceed.2014.11.018","article-title":"Safety and efficacy of induction treatment with low thymoglobulin doses in kidney transplantation from expanded-criteria donors","volume":"47","author":"Sancho Calabuig","year":"2015","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0245","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2362.2011.02490.x","article-title":"Long-term outcome of ATG vs. Basiliximab induction","volume":"41","author":"Ulrich","year":"2011","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.trre.2023.100795_bb0250","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ekir.2021.11.028","article-title":"A randomized controlled trial on safety of steroid avoidance in immunologically low-risk kidney transplant recipients","volume":"7","author":"Ekberg","year":"2022","journal-title":"Kidney Int Reports"},{"key":"10.1016\/j.trre.2023.100795_bb0255","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1093\/ndt\/gfl131","article-title":"Steroid-free immunosuppression after renal transplantation\u2014long-term experience from a single Centre","volume":"21","author":"El-Faramawi","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2023.100795_bb0260","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.transproceed.2011.12.055","article-title":"Induction therapy by anti-Thymocyte globulin (rabbit) versus Basiliximab in deceased donor renal transplants and the effect on delayed graft function and outcomes","volume":"44","author":"Foster","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0265","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.trim.2012.07.002","article-title":"The impact of terminal complement blockade on the efficacy of induction with polyclonal rabbit antithymocyte globulin in living donor renal allografts","volume":"27","author":"Goh","year":"2012","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.trre.2023.100795_bb0270","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.transproceed.2006.02.116","article-title":"Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or Basiliximab","volume":"38","author":"Heilman","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0275","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1097\/TP.0000000000002421","article-title":"CMV-specific cell-mediated immunity at 3-month prophylaxis withdrawal discriminates D+\/R+ kidney transplants at risk of late-onset CMV infection regardless the type of induction therapy","volume":"102","author":"Jarque","year":"2018","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0280","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14121","article-title":"Induction immunosuppression and the risk of incident malignancies among older and younger kidney transplant recipients: a prospective cohort study","volume":"34","author":"Wang","year":"2020","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2023.100795_bb0285","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/01.tp.0000165847.05787.08","article-title":"A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring","volume":"80","author":"Ciancio","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2023.100795_bb0290","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/01.TP.0000441089.39840.66","article-title":"Randomized trial of three induction antibodies in kidney transplantation: long-term results","volume":"97","author":"Ciancio","year":"2014","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0295","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.transproceed.2013.07.067","article-title":"Alemtuzumab and minimization immunotherapy in kidney transplantation: long-term results of comparison with rabbit anti-Thymocyte globulin and standard triple maintenance therapy","volume":"46","author":"Zachariah","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0300","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/ctr.12201","article-title":"Delayed allograft inflammation following alemtuzumab induction for kidney transplantation","volume":"27","author":"Heilman","year":"2013","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2023.100795_bb0305","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.2215\/CJN.13100820","article-title":"Belatacept for simultaneous Calcineurin inhibitor and chronic corticosteroid immunosuppression avoidance","volume":"16","author":"Kaufman","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2023.100795_bb0310","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1016\/j.transproceed.2014.08.037","article-title":"Alemtuzumab induction and antibody-mediated rejection in kidney transplantation","volume":"46","author":"Noureldeen","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0315","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/tri.13583","article-title":"Outcomes of induction antibody therapies in the nonbroadly sensitized adult deceased donor kidney transplant recipients: a retrospective cohort registry analysis","volume":"33","author":"Santos","year":"2020","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2023.100795_bb0320","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/ctr.12532","article-title":"Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal","volume":"29","author":"Saull","year":"2015","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2023.100795_bb0325","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.2215\/CJN.12161214","article-title":"Outcomes associated with steroid avoidance and Alemtuzumab among kidney transplant recipients","volume":"10","author":"Serrano","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2023.100795_bb0330","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/01.tp.0000281942.97406.89","article-title":"Alemtuzumab induction in deceased donor kidney transplantation","volume":"84","author":"Huang","year":"2007","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0335","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1097\/TP.0000000000001530","article-title":"Depleting antibody induction and kidney transplant outcomes: a paired kidney analysis","volume":"101","author":"Sampaio","year":"2017","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0340","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/01.TP.0000116442.81259.60","article-title":"Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: a single-center retrospective study","volume":"77","author":"Ducloux","year":"2004","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0345","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13680","article-title":"Effectiveness and safety of two different antithymocyte globulins used in induction therapy in kidney transplant recipients: A single-center experience","volume":"33","author":"Styrc","year":"2019","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2023.100795_bb0350","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/TP.0b013e31824491aa","article-title":"Differential regulation of the nuclear factor-\u03baB pathway by rabbit antithymocyte globulins in kidney transplantation","volume":"93","author":"Urbanova","year":"2012","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0355","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1097\/TP.0b013e3181a2475f","article-title":"Rabbit antithymocyte globulin is more beneficial in standard kidney than in extended donor recipients","volume":"87","author":"Hardinger","year":"2009","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0360","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.trim.2013.03.001","article-title":"Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial","volume":"28","author":"B\u00fcchler","year":"2013","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.trre.2023.100795_bb0365","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/00007890-200003150-00021","article-title":"Low dose antithymocyte globulins in renal transplantation: daily versus intermittent administration based on T-cell monitoring","author":"Djamali","year":"2000","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0370","doi-asserted-by":"crossref","first-page":"e104408","DOI":"10.1371\/journal.pone.0104408","article-title":"Immunophenotyping and efficacy of low dose ATG in non-sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study. Gregson A, ed","volume":"9","author":"Grafals","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.trre.2023.100795_bb0375","first-page":"2276","article-title":"Clinical and economic analysis of short-course versus standard-course antithymocyte globulin (rabbit) induction therapy in deceased-donor renal transplant recipients","volume":"68","author":"Marfo","year":"2011","journal-title":"Am J Heal Pharm AJHP Off J Am Soc Heal Pharm"},{"key":"10.1016\/j.trre.2023.100795_bb0380","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.12977","article-title":"The appropriate dose of thymoglobulin induction therapy in kidney transplantation","volume":"31","author":"Nafar","year":"2017","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2023.100795_bb0385","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1159\/000355620","article-title":"Renal transplantation in the setting of early steroid withdrawal: a comparison of rabbit antithymocyte globulin induction dosing in two eras","volume":"38","author":"Rogers","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.trre.2023.100795_bb0390","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/TP.0b013e318257ad1a","article-title":"Impact of small variations in the delivered dose of rabbit antithymocyte induction therapy in kidney transplantation with early corticosteroid withdrawal","volume":"94","author":"Tsapepas","year":"2012","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0395","first-page":"629","article-title":"Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation","volume":"19","author":"Wong","year":"2006","journal-title":"Transpl Int Off J Eur Soc Organ Transplant"},{"key":"10.1016\/j.trre.2023.100795_bb0400","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.trim.2012.02.003","article-title":"The effect of low and ultra-low dosages thymoglobulin on peripheral T, B and NK cells in kidney transplant recipients","volume":"26","author":"Kho","year":"2012","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.trre.2023.100795_bb0405","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1097\/TP.0b013e3181722fad","article-title":"Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report","volume":"85","author":"Stevens","year":"2008","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0410","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/ndt\/gfr693","article-title":"Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy","volume":"27","author":"Krystufkova","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2023.100795_bb0415","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2023.100795_bb0420","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1016\/S0041-1345(01)02357-0","article-title":"A pilot study comparing basiliximab and anti-thymocyte globulin as induction therapy in sensitized renal allograft recipients","volume":"33","author":"Mariat","year":"2001","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0425","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1111\/j.1600-6143.2006.01472.x","article-title":"Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG","volume":"6","author":"Vo","year":"2006","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"key":"10.1016\/j.trre.2023.100795_bb0430","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.trim.2007.08.002","article-title":"Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen","volume":"18","author":"Yang","year":"2008","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.trre.2023.100795_bb0435","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/TP.0000000000000031","article-title":"Antithymocyte globulin is associated with a lower incidence of De novo donor-specific antibodies in moderately sensitized renal transplant recipients","volume":"97","author":"Brokhof","year":"2014","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0440","first-page":"500","article-title":"Comparison of efficacy of induction therapy in low immunologic risk African-American kidney transplant recipients","volume":"23","author":"Fleming","year":"2010","journal-title":"Transpl Int Off J Eur Soc Organ Transplant"},{"key":"10.1016\/j.trre.2023.100795_bb0445","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13681","article-title":"Anti-IL-2R blockers comparing with polyclonal antibodies: higher risk of rejection without negative mid-term outcomes after ABO-incompatible kidney transplantation","volume":"33","author":"Del Bello","year":"2019","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2023.100795_bb0450","doi-asserted-by":"crossref","DOI":"10.1111\/tri.13428","article-title":"Increased risk of rejection after basiliximab induction in sensitized kidney transplant recipients without pre-existing donor-specific antibodies - a retrospective study","author":"Goumard","year":"2019","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2023.100795_bb0455","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/01.TP.0000153506.07816.F0","article-title":"Induction therapy with basiliximab versus thymoglobulin in African-American kidney transplant recipients","volume":"79","author":"Haririan","year":"2005","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0460","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1399-0012.2009.00974.x","article-title":"Efficacy of induction therapy on acute rejection and graft outcomes in African American kidney transplantation","volume":"24","author":"Hammond","year":"2010","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2023.100795_bb0465","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1111\/ajt.13191","article-title":"Daclizumab versus rabbit antithymocyte globulin in high-risk renal transplants: five-year follow-up of a randomized study","volume":"15","author":"Hellemans","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2023.100795_bb0470","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12882-015-0141-2","article-title":"Effect of induction therapy on the expression of molecular markers associated with rejection and tolerance","volume":"16","author":"Krepsova","year":"2015","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.trre.2023.100795_bb0475","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5414\/CN109934","article-title":"Alemtuzumab induction for retransplantation after primary transplant with alemtuzumab induction","volume":"93","author":"Descourouez","year":"2020","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.trre.2023.100795_bb0480","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","article-title":"Alemtuzumab induction in renal transplantation","volume":"364","author":"Hanaway","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2023.100795_bb0485","first-page":"664","article-title":"Alemtuzumab induction therapy in highly sensitized kidney transplant recipients","volume":"124","author":"L\u00fc","year":"2011","journal-title":"Chin Med J"},{"key":"10.1016\/j.trre.2023.100795_bb0490","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1432-2277.2008.00642.x","article-title":"Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death","volume":"21","author":"Schadde","year":"2008","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2023.100795_bb0495","doi-asserted-by":"crossref","first-page":"741","DOI":"10.4103\/1319-2442.134954","article-title":"Steroid maintenance in repeat kidney transplantation: influence of induction agents on outcomes","volume":"25","author":"Sureshkumar","year":"2014","journal-title":"Saudi J Kidney Dis Transplant"},{"key":"10.1016\/j.trre.2023.100795_bb0500","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/01.tp.0000263344.53000.a1","article-title":"Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation","volume":"83","author":"Thomas","year":"2007","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0505","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165233","article-title":"A comparison of two types of rabbit antithymocyte globulin induction therapy in immunological high-risk kidney recipients: a prospective randomized control study","volume":"11","author":"Burkhalter","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.trre.2023.100795_bb0510","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/TP.0b013e31816dd596","article-title":"Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients","volume":"85","author":"Gurk-Turner","year":"2008","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251384","article-title":"The influence of the antithymocyte globulin dose on clinical outcomes of patients undergoing kidney retransplantation","volume":"16","author":"Linhares","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.trre.2023.100795_bb0520","first-page":"511","article-title":"Effects of ideal versus total body weight dosage of rabbit antithymocyte globulin on outcomes of kidney transplant patients with high immunologic risk","volume":"14","author":"Vacha","year":"2016","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.trre.2023.100795_bb0525","doi-asserted-by":"crossref","first-page":"134","DOI":"10.6002\/ect.2012.0220","article-title":"Effect of a single intraoperative high-dose ATG-Fresenius on delayed graft function in donation after cardiac-death donor renal allograft recipients: a randomized study","volume":"11","author":"van den Hoogen","year":"2013","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.trre.2023.100795_bb0530","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/j.transproceed.2012.07.013","article-title":"Comparison of long-term effect of thymoglobulin treatment in patients with a high risk of delayed graft function","volume":"44","author":"Requi\u00e3o-Moura","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0535","first-page":"310","article-title":"Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function","volume":"11","author":"Chen","year":"2013","journal-title":"Exp Clin Transplant Off J Middle East Soc Organ Transplant"},{"key":"10.1016\/j.trre.2023.100795_bb0540","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1097\/00007890-200105150-00025","article-title":"A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function","volume":"71","author":"Hong","year":"2001","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0545","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/01.TP.0000134399.10352.E4","article-title":"The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function","volume":"78","author":"Knight","year":"2004","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0550","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1016\/j.transproceed.2019.02.061","article-title":"Effectiveness of thymoglobulin induction therapy in kidney transplant from deceased donor with mild to moderate acute kidney injury","volume":"51","author":"Lee","year":"2019","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0555","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/ijcp.12663","article-title":"Interleukin-2 receptor antagonist compared with antithymocyte globulin induction therapy in kidney transplantation from donors after cardiac death","volume":"183","author":"Peng","year":"2015","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1016\/j.trre.2023.100795_bb0560","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/01.tp.0000442505.10490.20","article-title":"Outcome and cost analysis of induction immunosuppression with IL2Mab or ATG in DCD kidney transplants","volume":"97","author":"Popat","year":"2014","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0565","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0041-1345(03)00574-8","article-title":"Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors","volume":"35","author":"Sanchez-Fructuoso","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0570","first-page":"89","article-title":"Alemtuzumab induction in kidney transplant recipients","volume":"32","author":"Sampaio","year":"2010","journal-title":"J Bras Nefrol"},{"key":"10.1016\/j.trre.2023.100795_bb0575","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.transproceed.2014.12.007","article-title":"Polyclonal versus monoclonal induction therapy in a calcineurin inhibitor-free immunosuppressive therapy in renal transplantation: a comparison of efficacy and costs","volume":"47","author":"Sanchez-Escuredo","year":"2015","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0580","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/TP.0b013e3181b6f38c","article-title":"Reduced dose rabbit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients","volume":"88","author":"Klem","year":"2009","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0585","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.transproceed.2004.12.200","article-title":"Long-term evolution of lymphocytes subsets after induction therapy based on continuous versus discontinuous administration of anti-thymocyte globulins in renal-transplant patients","volume":"37","author":"Esposito","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0590","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1399-0012.2009.01127.x","article-title":"A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with Thymoglobulin in living-donor kidney transplantation","volume":"24","author":"Woodle","year":"2010","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2023.100795_bb0595","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4103\/1319-2442.132155","article-title":"Comparison between spousal donor transplantation treated with anti-thymocyte globulin induction therapy and, living related donor transplantation treated with standard immunosuppression","volume":"25","author":"Demir","year":"2014","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.trre.2023.100795_bb0600","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/tri.13865","volume":"34","author":"de Sandes-Freitas","year":"2021","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2023.100795_bb0605","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/1319-2442.124459","article-title":"Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: long-term outcome","volume":"25","author":"Kesiraju","year":"2014","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.trre.2023.100795_bb0610","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12882-019-1293-2","article-title":"Induction therapy with thymoglobulin or interleukin-2 receptor antagonist for Chinese recipients of living donor renal transplantation: a retrospective study","volume":"20","author":"Qiu","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.trre.2023.100795_bb0615","doi-asserted-by":"crossref","first-page":"251","DOI":"10.33549\/physiolres.933736","article-title":"The effect of induction therapy on established CMV specific T cell immunity in living donor kidney transplantation","volume":"67","author":"Stranavova","year":"2018","journal-title":"Physiol Res"},{"key":"10.1016\/j.trre.2023.100795_bb0620","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s11255-016-1307-y","article-title":"Basiliximab versus rabbit antithymocyte globulin as induction therapy for living-related renal transplantation: a single-center experience","volume":"48","author":"Huang","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.trre.2023.100795_bb0625","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1016\/j.transproceed.2010.08.045","article-title":"Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation","volume":"42","author":"Ciancio","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0630","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13257","article-title":"Assessment of infectious complications in elderly kidney transplant recipients receiving induction with anti-thymocyte globulin vs basiliximab","volume":"22","author":"Pham","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2023.100795_bb0635","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/TP.0000000000002804","article-title":"Induction therapy in elderly kidney transplant recipients with low immunological risk","volume":"104","author":"Masset","year":"2020","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0640","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1159\/000334092","article-title":"Poor outcomes in elderly kidney transplant recipients receiving alemtuzumab induction","volume":"34","author":"Hurst","year":"2011","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.trre.2023.100795_bb0645","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.transproceed.2010.02.088","article-title":"Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis","volume":"42","author":"Liu","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0650","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.transproceed.2018.01.022","article-title":"Efficacy and safety of induction therapy in kidney transplantation: a network Meta-analysis","volume":"50","author":"Hwang","year":"2018","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0655","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20620","article-title":"Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model","volume":"20","author":"Jones-Hughes","year":"2016","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.trre.2023.100795_bb0660","article-title":"Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients","volume":"1","author":"Hill","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.trre.2023.100795_bb0665","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/TP.0b013e318257ad41","article-title":"Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis","volume":"93","author":"Morgan","year":"2012","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0670","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007151","article-title":"Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients: a systematic review and meta-analysis of randomized controlled trials","volume":"96","author":"Zheng","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.trre.2023.100795_bb0675","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s11255-020-02418-w","article-title":"Rabbit anti-thymocyte globulin (rATG) versus IL-2 receptor antagonist induction therapies in tacrolimus-based immunosuppression era: a meta-analysis","volume":"52","author":"Ali","year":"2020","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.trre.2023.100795_bb0680","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3389\/fimmu.2020.00457","article-title":"Thymoglobulin vs. ATG-fresenius as induction therapy in kidney transplantation: a bayesian network meta-analysis of randomized controlled trials","volume":"11","author":"Song","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.trre.2023.100795_bb0685","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/j.transproceed.2019.04.079","article-title":"Effectiveness of antithymocyte globulin induction dosing regimens in kidney transplantation patients: a network meta-analysis","volume":"51","author":"Lee","year":"2019","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2023.100795_bb0690","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1080\/14712598.2021.1960978","article-title":"Association between cumulative rATG induction doses and kidney graft outcomes and adverse effects in kidney transplant patients: a systematic review and meta-analysis","volume":"21","author":"Mohammadi","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.trre.2023.100795_bb0695","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s10157-017-1480-z","article-title":"Induction therapy of basiliximab versus antithymocyte globulin in renal allograft: a systematic review and meta-analysis","volume":"22","author":"Wang","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.trre.2023.100795_bb0700","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.trim.2012.08.006","article-title":"Alemtuzumab induction in renal transplantation: a meta-analysis and systemic review","volume":"27","author":"Zhang","year":"2012","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.trre.2023.100795_bb0705","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/tri.13079","article-title":"Center practice drives variation in choice of US kidney transplant induction therapy: a retrospective analysis of contemporary practice","volume":"31","author":"Dharnidharka","year":"2018","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2023.100795_bb0710","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1440-1797.2007.00859.x","article-title":"Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005","volume":"13","author":"Chang","year":"2008","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.trre.2023.100795_bb0715","first-page":"ii9","article-title":"Heterogeneity of induction therapy in Spain: changing patterns according to year, centre, indications and results","volume":"3","author":"Rodrigo","year":"2010","journal-title":"NDT Plus"},{"key":"10.1016\/j.trre.2023.100795_bb0720","doi-asserted-by":"crossref","first-page":"277","DOI":"10.12659\/AOT.890069","article-title":"Comparison of clinical outcome of low-dose and high-dose rabbit antithymocyte globulin induction therapy in renal transplantation: a single-center experience","volume":"19","author":"Yang","year":"2014","journal-title":"Ann Transplant"},{"key":"10.1016\/j.trre.2023.100795_bb0725","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/01.TP.0000081042.67285.91","article-title":"A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients","volume":"76","author":"Goggins","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2023.100795_bb0730","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/01.TP.0000056635.59888.EF","article-title":"A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine a in adult renal transplant recipients","volume":"75","author":"Charpentier","year":"2003","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0735","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/ajt.15102","article-title":"Lymphocyte depletion and risk of acute rejection in renal transplant recipients at increased risk for delayed graft function","volume":"19","author":"Ravindra","year":"2019","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"key":"10.1016\/j.trre.2023.100795_bb0740","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1053\/j.ajkd.2012.08.049","article-title":"Kidney transplantation in the older adult","volume":"61","author":"Knoll","year":"2013","journal-title":"Am J kidney Dis Off J Natl Kidney Found"},{"key":"10.1016\/j.trre.2023.100795_bb0745","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1097\/TP.0000000000003547","article-title":"Immunosuppression regimen use and outcomes in older and younger adult kidney transplant recipients: a National Registry Analysis","volume":"105","author":"Lentine","year":"2021","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2023.100795_bb0750","doi-asserted-by":"crossref","first-page":"100377","DOI":"10.1016\/j.xkme.2021.08.012","article-title":"Posttransplant diabetes mellitus and immunosuppression selection in older and obese kidney recipients","volume":"4","author":"Axelrod","year":"2022","journal-title":"Kidney Med"},{"key":"10.1016\/j.trre.2023.100795_bb0755","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.trre.2016.05.001","article-title":"Immunosuppression in the elderly renal allograft recipient: a systematic review","volume":"30","author":"Montero","year":"2016","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.trre.2023.100795_bb0760","article-title":"Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients","volume":"1","author":"Hill","year":"2017","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X23000496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X23000496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T16:09:13Z","timestamp":1760630953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X23000496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":152,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0955470X23000496"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2023.100795","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of lymphocyte-depleting antibodies in specific populations of kidney transplant recipients: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2023.100795","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100795"}}